Atherosclerosis is the leading cause of cardiovascular diseases and can begin silently, long before any symptoms appear.
According to a recent publication in the scientific journal Atheroma by the Hellenic Society of Lipidology, Atherosclerosis, and Vascular Disease, in which GENOSOPHY® participated, genetic testing can reveal inherited forms of hyperlipidemia and improve risk stratification, enabling more targeted interventions.
The guidelines of both the European and American Cardiology Societies confirm that genetic analysis is essential for the diagnosis and management of these conditions.
GENOSOPHY®’s Hyperlipidemia Genetic Test uses next-generation sequencing (NGS) technology to analyze genes such as LDLR, APOB, and PCSK9, which are associated with hypercholesterolemia, hypertriglyceridemia, and early-onset atherosclerosis.
With GENOSOPHY®’s support, you can understand your hereditary risk and tailor your prevention and treatment strategy accordingly.
Learn more about GENOSOPHY®’s Hyperlipidemia Genetic Test here.
